查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
支氣管擴張劑市場,份額,規模,趨勢,行業分析報告：按疾病,按給藥途徑,按藥物類別,按作用方式,按地區,細分市場預測，2023-2032年
市場調查報告書
商品編碼
1297955

支氣管擴張劑市場,份額,規模,趨勢,行業分析報告：按疾病,按給藥途徑,按藥物類別,按作用方式,按地區,細分市場預測，2023-2032年

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

據Polaris Market Research最新研究顯示，到2032年，全球支氣管擴張劑市場規模預計將達到308.8億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場增長進行了分析。

為了滿足臨床醫生和肺科醫生對使用新型支氣管擴張劑組合（例如短效 BETA-2 激動劑和皮質類固醇）來立即緩解症狀的日益增長的偏好和需求，這些將藥物商業化的主要行業參與者預計將大幅增加支氣管擴張劑的供應和採用。再加上全球人口老齡化，增加了患下呼吸道感染（LRTI）的風險，預計將促進市場增長。

例如，2023年1月，美國食品和藥物管理局批准Airsupra用於治療哮喘加重。這種創新的加壓計量平台採用沙丁胺醇/布地奈德組合作為救援療法，並輔以沙丁胺醇維持加強劑量。對速效支氣管擴張劑的需求不斷增長，推動了治療主要呼吸道疾病的各種組合藥物的批准，支持了市場增長。

最近呼吸醫學的研究表明，兒童支氣管收縮的病例有所增加，並且患者數量正在迅速增加。許多因素，包括遺傳和不健康的飲食習慣，使兒童容易患上哮喘等長期呼吸道疾病。據推測，兒科呼吸藥物的廣泛使用以及世界各地各醫療機構的宣傳活動和臨床研究正在支持市場的增長。

例如，NCBI 2022 年 8 月發布的一項研究估計，美國兒童哮喘患病率為 8.4%，估計患病人數超過 600 萬。此外，66.0%的兒童被發現患有嚴重哮喘，患病率很高。因此，兒科患者的增加以及現有患者庫預計將推動對支氣管擴張劑的需求，以用於嚴重病例的維持治療和支氣管緩解。

COVID-19 對支氣管擴張劑市場的影響是積極的，因為它可以促進患有冠狀病毒呼吸系統緊急情況的患者的正常呼吸。此外，這一時期肺炎等危及生命的疾病的高發導致支氣管擴張劑等呼吸系統藥物和支持性護理的大量湧入。再加上緊急方案和醫療保健指南的部署，推動了支氣管擴張劑的使用，並由於呼吸道疾病入院人數增加，在大流行期間促進了市場增長。

支氣管擴張劑市場報告亮點

  • 由於人們越來越意識到呼吸醫學中支氣管擴張劑治療的益處以及慢性阻塞性肺病患者的高患病率，預計慢性阻塞性肺病細分市場在預測期內將以高複合年增長率增長。
  • 由於口服藥物在減少支氣管收縮發作方面的高成功率以及黃嘌呤衍生物在支持治療中的使用越來越多，口服藥物佔據了最大的銷售份額。
  • 由於BETA-腎上腺素能激動劑在呼吸醫學領域的傳統智慧以及與其他類別支氣管擴張劑相比的有效治療特性，預計在預測期內將佔據較大的市場份額。
  • 由於空氣污染引起的支氣管炎和其他呼吸道疾病的發病率不斷增加，預計北美在預測期內將出現顯著增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章研究方法論

第四章全球支氣管擴張劑市場洞察

  • 支氣管擴張劑 - 行業快照
  • 支氣管擴張劑市場動態
    • 驅動因素和機遇
      • 哮喘和慢性阻塞性肺病的發病率增加
      • 新興國家的各種增長機會
    • 限制和挑戰
      • 與支氣管擴張劑相關的副作用
  • PESTLE分析
  • 支氣管擴張劑行業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

5.全球支氣管擴張劑市場（按疾病）

  • 主要發現
  • 介紹
  • 哮喘
  • 慢性阻塞性肺病
  • 其他

6. 全球支氣管擴張劑市場（按給藥途徑）

  • 主要發現
  • 介紹
  • 可吸入的
  • 口服
  • 注射

7.全球支氣管擴張劑市場，按藥物類別

  • 主要發現
  • 介紹
  • BETA-腎上腺素能激動劑
  • 抗膽鹼能藥
  • 黃嘌呤衍生物
  • 磷酸二酯□抑製劑
  • 配合劑

8. 全球支氣管擴張劑市場（按作用機制）

  • 主要發現
  • 介紹
  • 短效
  • 長效

第九章全球支氣管擴張劑市場（按地區）

  • 主要發現
  • 介紹
    • 支氣管擴張劑市場評估，地區，2019-2032
  • 支氣管擴張劑市場-北美
    • 北美：支氣管擴張劑市場，按疾病分類，2019-2032
    • 北美：支氣管擴張劑市場，按作用機制，2019-2032
    • 北美：2019-2032 年按給藥途徑劃分的支氣管擴張劑市場
    • 北美：支氣管擴張劑市場，按藥物類別，2019-2032
    • 支氣管擴張劑市場-美國
    • 支氣管擴張劑市場-加拿大
  • 支氣管擴張劑市場 - 歐洲
    • 歐洲：支氣管擴張劑市場，按疾病分類，2019-2032
    • 歐洲：支氣管擴張劑市場，按作用方式，2019-2032
    • 歐洲：2019-2032 年按給藥途徑劃分的支氣管擴張劑市場
    • 歐洲：支氣管擴張劑市場，按藥物類別，2019-2032
    • 支氣管擴張劑市場 - 英國
    • 支氣管擴張劑市場 - 法國
    • 支氣管擴張劑市場-德國
    • 支氣管擴張劑市場-意大利
    • 支氣管擴張劑市場-西班牙
    • 支氣管擴張劑市場 - 荷蘭
    • 支氣管擴張劑市場-俄羅斯
  • 支氣管擴張劑市場 - 亞太地區
    • 亞太地區：支氣管擴張劑市場，按疾病分類，2019-2032
    • 亞太地區：支氣管擴張劑市場，按作用機制，2019-2032
    • 亞太地區：按給藥途徑劃分的支氣管擴張劑市場，2019-2032 年
    • 亞太地區：支氣管擴張劑市場，按藥物類別，2019-2032
    • 支氣管擴張劑市場-中國
    • 支氣管擴張劑市場-印度
    • 支氣管擴張劑市場-日本
    • 支氣管擴張劑市場-馬來西亞
    • 支氣管擴張劑市場-印度尼西亞
    • 支氣管擴張劑市場-韓國
  • 支氣管擴張劑市場-中東和非洲
    • 中東和非洲：支氣管擴張劑市場，按疾病分類，2019-2032
    • 中東和非洲：支氣管擴張劑市場，按作用機制，2019-2032
    • 中東和非洲：2019-2032 年按給藥途徑劃分的支氣管擴張劑市場
    • 中東和非洲：支氣管擴張劑市場，按藥物類別，2019-2032
    • 支氣管擴張劑市場-沙特阿拉伯
    • 支氣管擴張劑市場-南非
    • 支氣管擴張劑市場-以色列
    • 支氣管擴張劑市場-阿拉伯聯合酋長國
  • 支氣管擴張劑市場 - 拉丁美洲
    • 拉丁美洲：支氣管擴張劑市場，按疾病分類，2019-2032 年
    • 拉丁美洲：支氣管擴張劑市場，按作用機制，2019-2032
    • 拉丁美洲：按給藥途徑劃分的支氣管擴張劑市場，2019-2032 年
    • 拉丁美洲：支氣管擴張劑市場，按藥物類別，2019-2032
    • 支氣管擴張劑市場-墨西哥
    • 支氣管擴張劑市場-巴西
    • 支氣管擴張劑市場-阿根廷

第10章 競爭格局

  • 擴張和收購分析
    • 擴張
    • 獲得
  • 聯盟/合作/協議/披露

第十一章公司簡介

  • GSK
  • AstraZeneca
  • Teva Pharmaceutical
  • Cipla Inc
  • Mylan
  • Merck
  • Novartis
  • Boehringer Ingelheim
  • Sun Pharmaceutical Industries
  • Glenmark Pharmaceuticals Limited
Product Code: PM3204

The global bronchodilators market size is expected to reach USD 30.88 billion by 2032, according to a new study by Polaris Market Research. The report "Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing preference of clinicians and respiratory experts on utilizing novel bronchodilator combinations such as short-acting beta 2 agonists along with corticosteroids for immediate relief along with key industry players commercializing these drugs to cater the rising demand is estimated to surge availability and adoption of bronchodilators. This coupled with rise in ageing population globally at a higher risk of developing Lower Respiratory Tract Infections (LRTI) are anticipated to augment the growth of the market.

For instance, in January 2023, the U.S. Food and Drug administration approved Airsupra for the therapy of Asthma with exacerbations. The innovative pressurized metering platform delivers the combination albuterol/budesonide as a rescue therapy, supplemented by maintenance of additional albuterol dose. The increasing need of quick acting bronchodilators is promoting key players in gaining approvals for various combinations to cater major respiratory disorders thereby supporting the growth of the market.

Recent studies in respiratory medicine have shown increasing occurrence of bronchoconstriction cases in children which is growing rapidly among the patient pool. Various factors such as genetics, unhealthy food habits, among others are making of pediatrics susceptible to long term respiratory conditions such as Asthma. This along with awareness campaigns and clinical research by various healthcare bodies around the globe, promoting pediatric respiratory medication is estimated to support the growth of the market.

For instance, a research study published by the NCBI, in August 2022, the prevalence of children suffering from Asthma in the U.S. was estimated to be 8.4%, estimated over 6 million patient population. Moreover, 66.0% of children were found to be suffering from severe cases of Asthma with a high morbidity rate. Therefore, the increasing presence of pediatric patients along with the existing patient pool is anticipated to drive the demand for bronchodilators owing to maintenance therapy and bronchial alleviation in cases of severity.

The impact of COVID-19 on the bronchodilator market was favorable due facilitation of normal breathing for patients affected by the corona virus induced respiratory emergencies. Moreover, high incidence rates of life threatening diseases such as pneumonia during the period demanded an inflow of respiratory medications and supportive therapies such as bronchodilation. This coupled with deployment of emergency protocols and healthcare guidelines, increasing hospital admissions with respiratory complaints promoted the use of bronchodilators thereby bolstering the growth of the market during the pandemic.

Bronchodilators Market Report Highlights

  • COPD segment is anticipated to grow at a high CAGR over the forecast period owing to rising awareness of bronchodilation therapy benefits in respiratory medicine along with high prevalence of COPD among patient population.
  • Oral accounted for largest revenue share which is accelerated by the higher success rates of oral drugs in reducing bronconstriction episodes along increasing applications of Xanthine derivatives in supportive therapies.
  • Beta-Adrenergics is expected to hold the significant market share over the forecast period due to its conventional wisdom in respiratory medicine along with effective treatment profile as compared to other classes of bronchodilators.
  • North America is expected to grow prominently over the projected period owing to increasing incidence of bronchitis and other respiratory disorders triggered due to air pollution.
  • The global players in the market include GSK, AstraZeneca, Teva Pharmaceutical, Cipla Inc., Mylan, Merck, Novartis, Boehringer Ingelheim, Sun Pharmaceutical, Glenmark Pharmaceuticals.

Polaris Market Research has segmented the bronchodilators market report based by disease, by route of administration, by drug class, by mode of action and region:

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

  • Asthma
  • COPD
  • Others

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Inhalable
  • Oral
  • Injection

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Beta-Adrenergics
  • Anticholinergics
  • Xanthine Derivatives
  • Phosphodiesterase Inhibitors
  • Combination Drugs

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

  • Short Acting
  • Long Acting

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Bronchodilators Market Insights

  • 4.1. Bronchodilators - Industry Snapshot
  • 4.2. Bronchodilators Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in incidence of asthma and COPD
      • 4.2.1.2. Various growth opportunities in emerging economies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Side effects associated with bronchodilators
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Bronchodilators Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Bronchodilators Market, by Disease

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • 5.3. Asthma
    • 5.3.1. Global Bronchodilators Market, by Asthma, by Region, 2019-2032 (USD Billion)
  • 5.4. COPD
    • 5.4.1. Global Bronchodilators Market, by COPD, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Bronchodilators Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Bronchodilators Market, by Route Of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • 6.3. Inhalable
    • 6.3.1. Global Bronchodilators Market, by Inhalable, by Region, 2019-2032 (USD Billion)
  • 6.4. Oral
    • 6.4.1. Global Bronchodilators Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 6.5. Injection
    • 6.5.1. Global Bronchodilators Market, by Injection, by Region, 2019-2032 (USD Billion)

7. Global Bronchodilators Market, by Drug Class

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.3. Beta-Adrenergics
    • 7.3.1. Global Bronchodilators Market, by Beta-Adrenergics, by Region, 2019-2032 (USD Billion)
  • 7.4. Anticholinergics
    • 7.4.1. Global Bronchodilators Market, by Anticholinergics, by Region, 2019-2032 (USD Billion)
  • 7.5. Xanthine Derivatives
    • 7.5.1. Global Bronchodilators Market, by Xanthine Derivatives, by Region, 2019-2032 (USD Billion)
  • 7.6. Phosphodiesterase Inhibitors
    • 7.6.1. Global Bronchodilators Market, by Phosphodiesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  • 7.7. Combination Drugs
    • 7.7.1. Global Bronchodilators Market, by Combination Drugs, by Region, 2019-2032 (USD Billion)

8. Global Bronchodilators Market, by Mode of Action

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • 8.3. Short Acting
    • 8.3.1. Global Bronchodilators Market, by Short Acting, by Region, 2019-2032 (USD Billion)
  • 8.4. Long Acting
    • 8.4.1. Global Bronchodilators Market, by Long Acting, by Region, 2019-2032 (USD Billion)

9. Global Bronchodilators Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Bronchodilators Market - North America
    • 9.3.1. North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.3.2. North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.3.3. North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.3.4. North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.5. Bronchodilators Market - U.S.
      • 9.3.5.1. U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.6. Bronchodilators Market - Canada
      • 9.3.6.1. Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.4. Bronchodilators Market - Europe
    • 9.4.1. Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.5. Bronchodilators Market - UK
      • 9.4.5.1. UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.6. Bronchodilators Market - France
      • 9.4.6.1. France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.7. Bronchodilators Market - Germany
      • 9.4.7.1. Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.8. Bronchodilators Market - Italy
      • 9.4.8.1. Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.9. Bronchodilators Market - Spain
      • 9.4.9.1. Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.10. Bronchodilators Market - Netherlands
      • 9.4.10.1. Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.11. Bronchodilators Market - Russia
      • 9.4.11.1. Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.5. Bronchodilators Market - Asia Pacific
    • 9.5.1. Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.5. Bronchodilators Market - China
      • 9.5.5.1. China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.6. Bronchodilators Market - India
      • 9.5.6.1. India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.7. Bronchodilators Market - Japan
      • 9.5.7.1. Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.8. Bronchodilators Market - Malaysia
      • 9.5.8.1. Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.9. Bronchodilators Market - Indonesia
      • 9.5.9.1. Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.10. Bronchodilators Market - South Korea
      • 9.5.10.1. South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.6. Bronchodilators Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.5. Bronchodilators Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.6. Bronchodilators Market - South Africa
      • 9.6.6.1. South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.7. Bronchodilators Market - Israel
      • 9.6.7.1. Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.8. Bronchodilators Market - UAE
      • 9.6.8.1. UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.7. Bronchodilators Market - Latin America
    • 9.7.1. Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.5. Bronchodilators Market - Mexico
      • 9.7.5.1. Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.6. Bronchodilators Market - Brazil
      • 9.7.6.1. Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.7. Bronchodilators Market - Argentina
      • 9.7.7.1. Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. GSK
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. AstraZeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Teva Pharmaceutical
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Cipla Inc
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Mylan
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Merck
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Novartis
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Boehringer Ingelheim
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Sun Pharmaceutical Industries
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Glenmark Pharmaceuticals Limited
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development

List of Tables

  • Table 1 Global Bronchodilators Market, by Disease, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Bronchodilators Market, by Route Of Administration, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Bronchodilators Market, by Drug Class, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Bronchodilators Market, by Mode of Action, by Region, 2019-2032 (USD Billion)
  • Table 5 Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 7 North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 8 North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 10 U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 11 U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 12 U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 13 U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 14 Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 15 Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 16 Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 18 Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 19 Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 20 Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 22 Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 23 Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 24 Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 25 Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 26 France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 27 France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 28 France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 30 UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 31 UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 32 UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 34 Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 35 Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 36 Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 37 Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 42 Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 43 Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 44 Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 46 Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 47 Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 48 Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 49 Russia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 54 China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 55 China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 56 China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 China: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 58 Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 59 Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 60 Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 61 Japan: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 62 India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 63 India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 64 India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 65 India: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 74 South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 75 South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 76 South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 77 South Korea: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 78 Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 79 Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 80 Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 82 Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 83 Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 84 Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 85 Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 86 Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 87 Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 88 Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 89 Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 90 Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 91 Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 92 Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 93 Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 98 UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 99 UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 100 UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 101 UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 106 South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 107 South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 108 South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 109 South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 110 Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 111 Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 112 Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 113 Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Bronchodilators Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Mode of Action
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease
  • Figure 7. Global Bronchodilators Market, by Disease, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Mode of Action
  • Figure 9. Global Bronchodilators Market, by Mode of Action, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Route Of Administration
  • Figure 11. Global Bronchodilators Market, by Route Of Administration, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Drug Class
  • Figure 13. Global Bronchodilators Market, by Drug Class, 2021 & 2030 (USD Billion)